Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Florbetapir

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Florbetapir. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2020-002511-22 Sponsor Protocol Number: 20-05 Start Date*: 2023-06-08
    Sponsor Name:Amsterdam UMC VUmc
    Full Title: Synaptic density and tau pathology in Alzheimer's disease
    Medical condition: Amyloid-beta positive individuals across the Alzheimer's disease continuum
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023852-10 Sponsor Protocol Number: 18F-AV-45-020 Start Date*: 2011-10-03
    Sponsor Name:Avid Radiopharmaceuticals, Inc.
    Full Title: 18F-AV-45 Amyloid PET Imaging in Primary Progressive Aphasia
    Medical condition: Focal dementia syndromes - primary aphasia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10012292 Dementia of the Alzheimer's type NOS LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-003079-20 Sponsor Protocol Number: 18F-AV-45-C02 Start Date*: 2013-01-10
    Sponsor Name:AVID RADIOPHARMACEUTICALS, INC.
    Full Title: Evaluation of florbetapir (18F) PET in subjects participating in the IRCCSFBF protocol
    Medical condition: Alzheimer's disease and other neurodegenerative diseases, as for example Dementia with Lewy bodies, Parkinson Dementia, Vascular Dementia and Tau Protein associated Dementia.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    14.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    14.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-001315-40 Sponsor Protocol Number: RF-2010-2319722 Start Date*: 2014-12-03
    Sponsor Name:IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli
    Full Title: Amyloid Imaging in the “Italian Network for autosomal dominant Alzheimer’s disease and frontotemporal lobar degeneration (ItalianDIAfN)”
    Medical condition: Autosomal Dominant Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001599-12 Sponsor Protocol Number: 18F-AV-45-C01 Start Date*: 2014-03-04
    Sponsor Name:VU University Medical Center (VUmc)
    Full Title: The clinical value of amyloid imaging with [18F]-AV45 in a population of memory clinic patients
    Medical condition: The total number of inclusion in this study is 170 subjects; 140 patients (including Alzheimer’s disease (AD) patients, patients with mild cognitive impairment (MCI), patients with subjective memor...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002595-13 Sponsor Protocol Number: 18F-AV-45-A18 Start Date*: 2013-03-01
    Sponsor Name:AVID RADIOPHARMACEUTICALS, INC.
    Full Title: A randomized, multicenter, multicountry study to evaluate the effectiveness of Florbetapir (18F) PET imaging in changing patient management and to evaluate the relationship between Florbetapir (1...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022598-32 Sponsor Protocol Number: ABE4955g Start Date*: 2011-07-13
    Sponsor Name:Genentech Inc
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTER, PHASE II STUDY TO EVALUATE THE IMPACT OF MABT5102A ON BRAIN AMYLOID LOAD AND RELATED BIOMARKERS IN PATIENTS WITH MILD TO...
    Medical condition: Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-005217-37 Sponsor Protocol Number: I4O-MC-BACC(b) Start Date*: 2012-08-22
    Sponsor Name:Eli Lilly and Company
    Full Title: Assessment of Safety, Tolerability, and Pharmacodynamic Effects of LY2886721 in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer's Disease
    Medical condition: Mild Cognitive Impairment Due to Alzheimer’s Disease or Mild Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003597-18 Sponsor Protocol Number: 18F-AV-45-010 Start Date*: 2009-05-28
    Sponsor Name:Avid Radiopharmaceuticals, Inc
    Full Title: A study evaluating the imaging characteristics of 18F-AV-45 in patients with frontotemporal dementia compared to patients with Alzheimer's disease and normal controls
    Medical condition: Use of 18F-AV-45 positron emission tomography as early diagnostic technique in frontal lobe dementia and Alzheimer's disease.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022891 - Investigations 10061816 Diagnostic procedure PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003705-42 Sponsor Protocol Number: 15-09 Start Date*: 2016-02-18
    Sponsor Name:VU University Medical Center
    Full Title: Longitudinal imaging of tau accumulation in the preclinical stages of AD
    Medical condition: Alzheimer's Disease (AD), preclincal stages of AD
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    20.0 10029205 - Nervous system disorders 10001897 Alzheimer's disease (incl subtypes) HLT
    20.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    20.0 10029205 - Nervous system disorders 10074616 Prodromal Alzheimer's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-012394-35 Sponsor Protocol Number: CCAD106A2203 Start Date*: 2010-03-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 90-week, multi-center, randomized, double-blind, placebo-controlled study in patients with mild Alzheimer’s Disease (AD) to investigate the safety, tolerability and Abeta-specific antibody respon...
    Medical condition: Alzheimer's Disease.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) SE (Completed) ES (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000108-27 Sponsor Protocol Number: H8A-MC-LZBE Start Date*: 2016-08-25
    Sponsor Name:Eli Lilly and Company
    Full Title: A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab versus Placebo in Prodromal Alzheimer’s Disease
    Medical condition: Prodromal Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005625-39 Sponsor Protocol Number: I8D-MC-AZET Start Date*: 2016-09-16
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s Disease Dementia (The DAYBREAK Study)
    Medical condition: Alzheimer’s Disease with Dementia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) DK (Completed) NL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-003390-95 Sponsor Protocol Number: WN28745 Start Date*: 2014-02-26
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A Phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter efficacy and safety study of Gantenerumab in patients with Mild Alzheimer’s disease: Part II: Open-label exten...
    Medical condition: MILD ALZHEIMER’S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001897 Alzheimer's disease (incl subtypes) HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) ES (Completed) PT (Completed) IT (Completed) NL (Completed) BE (Completed) HU (Completed) FI (Completed) BG (Completed) DK (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-003284-19 Sponsor Protocol Number: CTU/2013/073 Start Date*: 2017-01-24
    Sponsor Name:University College London
    Full Title: DEpletion of Serum amyloid P component In Alzheimer’s Disease: DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer’s disease.
    Medical condition: Alzheimer's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-001119-54 Sponsor Protocol Number: H8A-MC-LZAX Start Date*: 2013-09-27
    Sponsor Name:Eli Lilly and Company
    Full Title: Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) versus Placebo
    Medical condition: Mild Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) IT (Completed) SE (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000163-89 Sponsor Protocol Number: COG0104 Start Date*: 2018-04-23
    Sponsor Name:Cognition Therapeutics, Inc.
    Full Title: A Pilot Study to Evaluate the Effect of CT1812 Treatment on Aβ Oligomer Displacement into CSF in Subjects with Mild to Moderate Alzheimer's Disease Followed by a Six-Month Open Label Extension of a...
    Medical condition: Sponsor is developing an oral formulation of CT1812 fumarate to treat AD and mild cognitive impairment.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000604-15 Sponsor Protocol Number: PTC-19-602325 Start Date*: 2020-10-29
    Sponsor Name:UNIVERSITÀ DEGLI STUDI "G. D'ANNUNZIO" CHIETI-PESCARA
    Full Title: Multicentre, randomized, double-blind, placebo-controlled, parallel-group Phase II study aimed at evaluating the efficacy and safety of “Zinco Solfato” in Mild Cognitive Impairment due to Alzheimer...
    Medical condition: Prodromic Alzheimer's disease with evidence of cerebral amyloidosis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000307-17 Sponsor Protocol Number: DIAN-TU-001 Start Date*: 2014-01-08
    Sponsor Name:Washington University in St. Louis
    Full Title: A Phase II/III randomized, double-blind, placebo-controlled, cognitive endpoint, multicenter study of potential disease modifying therapies in individuals at risk for and with dominantly inherited ...
    Medical condition: Dominantly Inherited Alzheimer Disease (DIAD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned) ES (Temporarily Halted) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000077-25 Sponsor Protocol Number: I5T-MC-AACI Start Date*: 2020-07-13
    Sponsor Name:Eli Lilly and Company
    Full Title: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
    Medical condition: Early Symptomatic Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 01:56:52 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA